The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Efficacy & safety of standard of care cilta-cel in R/R multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the safety and efficacy data of ciltacabtagene autoleucel (cilta-cel) as a standard of care treatment for relapsed/refractory (R/R) multiple myeloma. High response rates (R/R) were observed, including in patients who would’ve been ineligible for the CARITITUDE-1 trial (NCT03548207). Dr Sidana explains that whilst no new toxicity signals were reported, some patients experienced delayed neurotoxicity and infections. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
